In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

Across patients with high-risk disease, median OS was significantly improved for the 4 patients who received an IDH1 inhibitor, either ivosidenib or olutasidenib, compared with the 28 patients who ...